Nurix Therapeutics Inc
For the period ended Feb 29, 2024. Filed Apr 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 29, 2024 · Filed Apr 10, 2024
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| February 29,2024 | November 30,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $49,813 | $54,627 |
| Marketable securities, current | 194,180 | 233,281 |
| Prepaid expenses and other current assets | 6,976 | 7,595 |
| Total current assets | 250,969 | 295,503 |
| Marketable securities, non‑current | 10,292 | 7,421 |
| Operating lease right-of-use assets | 29,299 | 31,142 |
| Property and equipment, net | 17,871 | 16,808 |
| Restricted cash | 901 | 901 |
| Other assets | 3,342 | 3,823 |
| Total assets | $312,674 | $355,598 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,918 | $6,401 |
| Accrued expenses and other current liabilities | 28,318 | 24,970 |
| Operating lease liabilities, current | 7,310 | 7,489 |
| Deferred revenue, current | 46,077 | 48,098 |
| Total current liabilities | 87,623 | 86,958 |
| Operating lease liabilities, net of current portion | 21,846 | 23,125 |
| Deferred revenue, net of current portion | 34,457 | 45,022 |
| Total liabilities | 143,926 | 155,105 |
| Commitments and contingencies (Note 6) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of February 29, 2024 and November 30, 2023; no shares issued and outstanding as of February 29, 2024 and November 30, 2023 | — | — |
| Common stock, $0.001 par value— 500,000,000 shares authorized as of February 29, 2024 and November 30, 2023; 49,136,954 and 48,718,552 shares issued and outstanding as of February 29, 2024 and November 30, 2023, respectively | 49 | 49 |
| Additional paid-in capital | 755,767 | 746,299 |
| Accumulated other comprehensive loss | (350) | (655) |
| Accumulated deficit | (586,718) | (545,200) |
| Total stockholdersʼ equity | 168,748 | 200,493 |
| Total liabilities and stockholdersʼ equity | $312,674 | $355,598 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.